Helius Medical Soars 40.97% on CignaHealth Authorization

Before the BellWednesday, Jun 18, 2025 4:55 am ET

1min read

On June 18, 2025, Helius Medical's stock surged by 40.97% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.

Helius Medical Technologies, Inc. recently announced that CignaHealth has become the fifth major payer to authorize claims for payment for the PoNS Device. This authorization follows a similar move by Anthem MultiPlan, indicating a growing acceptance of the device within the healthcare industry.

This development is a critical step towards wider adoption of the PoNS Device, as it enhances patient access and potential revenue streams for Helius Medical. The company's efforts in securing insurance reimbursement for the PoNS Device are expected to boost its market presence and financial performance.

The authorization by CignaHealth is likely to have a positive impact on Helius Medical's share price, as it increases the device's accessibility to a broader patient base. This move is part of Helius Medical's broader strategy to expand the use of its innovative technology in the treatment of neurological conditions.

Comments

﻿

Add a public comment...

No comments yet

Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.